An assessment of conformance to structured reporting framework in 68Ga prostate-specific membrane antigen PET/computed tomography for prostate cancer staging.

IF 1.3 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Jagrati Chaudhary, Sanjay Kumar, Param Dev Sharma, Kunhi Parambath Haresh, Rakesh Kumar, Chandan J Das, Ranjit Kumar Sahoo, Seema Kaushal, M Kalaivani, Anil Kumar Pandey
{"title":"An assessment of conformance to structured reporting framework in 68Ga prostate-specific membrane antigen PET/computed tomography for prostate cancer staging.","authors":"Jagrati Chaudhary, Sanjay Kumar, Param Dev Sharma, Kunhi Parambath Haresh, Rakesh Kumar, Chandan J Das, Ranjit Kumar Sahoo, Seema Kaushal, M Kalaivani, Anil Kumar Pandey","doi":"10.1097/MNM.0000000000002048","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>68Ga prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) plays a critical role in prostate cancer management. Most clinical reports, however, remain unstructured, increasing the risk of omitting essential diagnostic information. Although standardized frameworks such as PROMISE (Prostate Cancer Molecular Imaging Standardized Evaluation) have been proposed to improve consistency, real-world adherence remains variable. This study assessed the adequacy of 68Ga PSMA PET/CT reports and evaluated their alignment with PROMISE recommendations.</p><p><strong>Methods: </strong>A total of 189 68Ga PSMA PET/CT reports were retrospectively reviewed and scored based on the presence (1) or absence (0) of six diagnostic elements: primary tumor localization, PSMA uptake intensity, lymph node involvement, bone metastases, visceral metastases, and seminal vesicle involvement. Reports were classified as clinically adequate (score ≥5), partially adequate (3-4), or inadequate (<3). A one-sample z test assessed whether the proportion of adequate reports met a 90% benchmark (α = 0.05). Chi-square tests evaluated differences in reporting frequencies across elements.</p><p><strong>Results: </strong>None of the reports (0%) were inadequate. Of 189 reports, 95 (50.3%) were clinically adequate (score ≥5) and 94 (49.7%) were partially adequate (score 3-<5), with a significant overall adequacy rate (P < 0.0001). A notable gap existed between documentation of seminal vesicle involvement and prostate size (P < 0.0001). Despite consistent reporting of anatomical localization and molecular imaging tumour, node, metastases (miTNM) classification, key elements were often missing, including PSMA uptake metrics, lesion size, nodal features, CT parameters, imaging protocol, and reader confidence.</p><p><strong>Conclusion: </strong>In this single-center study, free-text 68Ga PSMA PET/CT reports were adequate for clinical needs but demonstrated only partial conformity to the PROMISE framework.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine Communications","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MNM.0000000000002048","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: 68Ga prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) plays a critical role in prostate cancer management. Most clinical reports, however, remain unstructured, increasing the risk of omitting essential diagnostic information. Although standardized frameworks such as PROMISE (Prostate Cancer Molecular Imaging Standardized Evaluation) have been proposed to improve consistency, real-world adherence remains variable. This study assessed the adequacy of 68Ga PSMA PET/CT reports and evaluated their alignment with PROMISE recommendations.

Methods: A total of 189 68Ga PSMA PET/CT reports were retrospectively reviewed and scored based on the presence (1) or absence (0) of six diagnostic elements: primary tumor localization, PSMA uptake intensity, lymph node involvement, bone metastases, visceral metastases, and seminal vesicle involvement. Reports were classified as clinically adequate (score ≥5), partially adequate (3-4), or inadequate (<3). A one-sample z test assessed whether the proportion of adequate reports met a 90% benchmark (α = 0.05). Chi-square tests evaluated differences in reporting frequencies across elements.

Results: None of the reports (0%) were inadequate. Of 189 reports, 95 (50.3%) were clinically adequate (score ≥5) and 94 (49.7%) were partially adequate (score 3-<5), with a significant overall adequacy rate (P < 0.0001). A notable gap existed between documentation of seminal vesicle involvement and prostate size (P < 0.0001). Despite consistent reporting of anatomical localization and molecular imaging tumour, node, metastases (miTNM) classification, key elements were often missing, including PSMA uptake metrics, lesion size, nodal features, CT parameters, imaging protocol, and reader confidence.

Conclusion: In this single-center study, free-text 68Ga PSMA PET/CT reports were adequate for clinical needs but demonstrated only partial conformity to the PROMISE framework.

68Ga前列腺特异性膜抗原PET/计算机断层扫描前列腺癌分期对结构化报告框架的符合性评估
背景:68Ga前列腺特异性膜抗原(PSMA) PET/ CT在前列腺癌的治疗中起着至关重要的作用。然而,大多数临床报告仍然是非结构化的,这增加了遗漏基本诊断信息的风险。虽然标准化框架如PROMISE(前列腺癌分子成像标准化评估)已被提出以提高一致性,但现实世界的依从性仍然是可变的。本研究评估了68Ga PSMA PET/CT报告的充分性,并评估了它们与PROMISE建议的一致性。方法:回顾性回顾189例68Ga PSMA PET/CT报告,并根据6项诊断要素的存在(1)或不存在(0)进行评分:原发肿瘤定位、PSMA摄取强度、淋巴结受累、骨转移、内脏转移和精囊受累。报告被分为临床充分(评分≥5)、部分充分(3-4)和不充分(结果:没有报告(0%)不充分)。在189份报告中,95份(50.3%)临床充足(评分≥5),94份(49.7%)部分充足(评分3)。结论:在这项单中心研究中,自由文本68Ga PSMA PET/CT报告足以满足临床需求,但仅部分符合PROMISE框架。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
6.70%
发文量
212
审稿时长
3-8 weeks
期刊介绍: Nuclear Medicine Communications, the official journal of the British Nuclear Medicine Society, is a rapid communications journal covering nuclear medicine and molecular imaging with radionuclides, and the basic supporting sciences. As well as clinical research and commentary, manuscripts describing research on preclinical and basic sciences (radiochemistry, radiopharmacy, radiobiology, radiopharmacology, medical physics, computing and engineering, and technical and nursing professions involved in delivering nuclear medicine services) are welcomed, as the journal is intended to be of interest internationally to all members of the many medical and non-medical disciplines involved in nuclear medicine. In addition to papers reporting original studies, frankly written editorials and topical reviews are a regular feature of the journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信